Pembrolizumab monotherapy in Japanese patients with advanced ovarian cancer: Subgroup analysis from the KEYNOTE-100.

Cancer Sci · 2020 · PMC7156846 · PMID 32012411

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

There was a favorable trend for OS in the Japanese subpopulation, which might reflect the fewer prior lines of therapy and slightly longer PFI/TFI profiles (6‐12 months) as well as the better ECOG performance status compared with the overall population.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.